In human prostate cancer cell lines, iCRT3 treatment is reported to decrease cell viability in vitro associated with reduced transcription of Wnt and AR target genes, and an additive effect was observed when iCRT3 was combined with enzalutamide, supporting the notion that suppressing β-catenin functions may be an effective treatment for enzalutamide resistant CRPC [55,235]. The gene discussed is AR; the disease is prostate carcinoma.